Key result
Alternate-day low-dose aspirin (100 mg) and vitamin E (600 IU) did not significantly reduce the primary composite cardiovascular endpoint in healthy women over 10 years.
Why the study?
Does alternate-day low-dose aspirin or vitamin E prevent cardiovascular events or cancer in healthy women aged 45 years and older?
RCT (n=39,876)
Randomized
Does alternate-day low-dose aspirin or vitamin E prevent cardiovascular events or cancer in healthy women aged 45 years and older?
In healthy women aged 45 and older, alternate-day low-dose aspirin prevents stroke but does not reduce the primary composite of MI, stroke, or CV death, while vitamin E provides no cardiovascular or cancer prevention benefits.
Does not support routine alternate-day aspirin or vitamin E for primary prevention in healthy women; confirms limited efficacy in low-risk populations.
Low-dose aspirin taken every other day helps prevent stroke in women aged 45 years and older, but does not prevent a first myocardial infarction (MI) or cardiovascular death among healthy women. Women receive no benefit from alternate-day vitamin E in the primary prevention of cardiovascular disease or cancer. These were the findings of the Women's Health Study, in which investigators followed 39,876 female health professionals over 10 years. The women were randomized to receive either 100 mg of aspirin or a placebo tablet every other day; they were also randomized to take 600 IU of vitamin E or a placebo capsule on the intervening days. No statistically significant differences were seen between the aspirin and placebo groups in the primary cardiovascular end point, which was the combined number of nonfatal MIs, nonfatal strokes, and cardiovascular deaths. Analysis of secondary cardiovascular end points revealed that aspirin use was associated with no significant effect on the number of total MIs, fatal MIs, and nonfatal MIs, and a nonsignificant decrease in cardiovascular mortality. However, aspirin users did experience significantly fewer strokes, in particular ischemic strokes. Vitamin E had very little impact on the primary prevention of both cardiovascular events and cancer.
No takes yet. Share an insight, caveat, or question.
Julie E. Buring (2006) conducted an RCT in Primary prevention of cardiovascular disease and cancer (n=39,876). Aspirin and Vitamin E vs. Placebo was evaluated on Combined number of nonfatal MIs, nonfatal strokes, and cardiovascular deaths. Alternate-day low-dose aspirin (100 mg) and vitamin E (600 IU) did not significantly reduce the primary composite cardiovascular endpoint in healthy women over 10 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: